FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV

Jason Mast

Editor

The FDA has cleared a company trying to use CRISPR gene-editing to cure HIV to begin clinical trials.

The study, run by the startup Excision BioTherapeutics, will likely begin early next year, CMO Lisa Danzig said, after final details are hashed out. It will involve three groups of three healthy HIV patients, with each group given a sequentially higher dose as the company tests the safety of the new therapy.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV

Jason Mast

Editor

To read Endpoints News become a free subscriber

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

FDA clears first-of-its-kind tri­al to see if CRISPR gene edit­ing can cure HIV

Jason Mast

Editor

To read Endpoints News become a free subscriber

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape